---
title: "STIEFEL LABORATORIES (U.K.) LTD — Ownership Dossier"
canonical: https://whiteintel.dev/entity/4c7c40dc-b177-5d25-b406-366d1b74d7b2
json: https://whiteintel.dev/api/public/dossier/4c7c40dc-b177-5d25-b406-366d1b74d7b2
identifier: oo:GB-COH-00831160
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# STIEFEL LABORATORIES (U.K.) LTD

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `oo:GB-COH-00831160`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/4c7c40dc-b177-5d25-b406-366d1b74d7b2  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/4c7c40dc-b177-5d25-b406-366d1b74d7b2  

## Ownership & control

### Owners / controllers

- **SETFIRST LIMITED** (beneficial owner) — 75% — https://whiteintel.dev/entity/c3d8f5a8-81f6-5054-8112-e2ec1616323f
- **GLAXOSMITHKLINE FINANCE PLC** (beneficial owner) — 50% — https://whiteintel.dev/entity/afa0ea64-4121-5dbd-aad0-1867fb9df850
- **Glaxosmithkline Finance Plc** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/c4260dcc-2978-4402-9aeb-307778f2117e
- **Setfirst Limited** (beneficial owner) — 62.5% — https://whiteintel.dev/entity/b2825d29-b940-410d-8d9b-0af637177e29
- **GSK FINANCE (NO 2) LIMITED** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/cee5e05f-87ce-58ed-8431-53bb40243cc8

### UBO chain (walk to the ultimate owner)

A **18-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Company profile (live · UK Companies House)

- **Company number:** `00831160`
- **Status:** active
- **Type:** ltd
- **Incorporated:** 1964-12-15
- **Registered office:** 79 New Oxford Street, London, WC1A 1DG, United Kingdom
- **SIC:** 74990

### Officers

- EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED — corporate secretary · appointed 2010-04-15
- GUITTARD, Laura — director · British,French · appointed 2022-01-11
- EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED — corporate director · appointed 2009-07-23
- [GLAXO GROUP LIMITED](https://whiteintel.dev/entity/bc15a382-b626-4703-b25a-5893cefaa340) — corporate director · appointed 2009-07-23
- DEVINE, David William — secretary · British · appointed 2007-01-02 · resigned 2010-03-31
- HOBBS, Michael — secretary · British · resigned 1997-06-12
- ZDANOWICZ, Margaret Eithne — secretary · British · appointed 1997-07-17 · resigned 2007-07-20
- BERTRAM, Bruno — director · French · resigned 2002-09-30
- DAVID, Brian Thomas — director · British · resigned 2006-12-31
- DEVINE, David William — director · British · appointed 2009-03-31 · resigned 2010-03-31
- HARDEN, James Walter — director · British · resigned 1996-05-31
- HUGHES, Michael Donald — director · British · appointed 1999-07-01 · resigned 2016-01-29
- JAITLY, Seema, Dr — director · British · appointed 2009-02-13 · resigned 2011-02-21
- LATCHFORD, Richard John — director · British · appointed 2019-04-25 · resigned 2020-03-02
- LYNCH, Ciara Martha — director · Irish · appointed 2020-03-02 · resigned 2022-01-11
- NELSON-JONES, John Austen — director · British · resigned 1995-01-17
- PANAGIOTIDIS, Charalampos — director · Greek · appointed 2019-02-15 · resigned 2020-03-02
- SKINNER, Brian John — director · British · resigned 1998-03-31
- STIEFEL, Charles — director · U S · appointed 2006-10-01 · resigned 2007-02-01
- STIEFEL, Herbert Arthur — director · Usa · resigned 2006-09-30

### Beneficial owners (Persons with Significant Control)

- [Gsk Finance (No 2) Limited](https://whiteintel.dev/entity/cee5e05f-87ce-58ed-8431-53bb40243cc8) — 25–50% shares · corporate PSC · England — since 2021-08-19
- [Setfirst Limited](https://whiteintel.dev/entity/b2825d29-b940-410d-8d9b-0af637177e29) — 50–75% shares · corporate PSC · United Kingdom — since 2016-04-06
- [Glaxosmithkline Finance Plc](https://whiteintel.dev/entity/c4260dcc-2978-4402-9aeb-307778f2117e) — 25–50% shares · corporate PSC · United Kingdom — ceased 2021-08-19

## Provenance

- OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/00831160
- companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/00831160

## Get the full, resolved dossier (agent-callable)

The above is the free teaser. The resolved **multi-hop UBO chain**, ownership **%**, full **financial history**, itemised **assets** and the hop-by-hop **exposure path** are the paid depth — callable as tools from your agent:

```bash
npx -y @whiteintel/mcp-server   # then: get_dossier · trace_ownership_path · check_offshore_exposure
```

Or unlock a one-off cited dossier for **STIEFEL LABORATORIES (U.K.) LTD** — https://whiteintel.dev/entity/4c7c40dc-b177-5d25-b406-366d1b74d7b2 · pricing https://whiteintel.dev/pricing.

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **STIEFEL LABORATORIES (U.K.) LTD**. Human view: https://whiteintel.dev/entity/4c7c40dc-b177-5d25-b406-366d1b74d7b2 · Structured JSON: https://whiteintel.dev/api/public/dossier/4c7c40dc-b177-5d25-b406-366d1b74d7b2._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._